Current therapy of retrolental fibroplasia. Retinopathy of prematurity.
Current therapy of retrolental fibroplasia. Retinopathy of prematurity.
复制标题
目前晶状体后纤维增生的治疗。
DOI：
10.1016/s0161-6420(83)34536-x
复制
发表时间：
1983
期刊：
影响因子：
13.7
通讯作者：
A. Patz
中科院分区：
文献类型：
--
作者：
A. Patz
视网膜纤维增生，现在常被称为“早产儿视网膜病变”，近年来发病率有所增加。这显然是由于新生儿护理的进步，导致极低出生体重儿的存活率提高了4至5倍，而这些婴儿患晶状体后纤维增生的风险最高。使用大量补充维生素E，一种已知的抗氧化剂，讨论沿着与其他形式的治疗。
Retrolental fibroplasia, frequently referred to now as the “retinopathy of prematurity,” has shown an increased incidence in recent years. This is apparently due to advances in neonatal care, which have resulted in a fourto five-fold improvement in the survival of the extremely low birth weight infants and it is these infants who are at the highest risk of developing retrolental fibroplasia. The use of large supplements of vitamin E, a known antioxidant, is discussed along with other forms of therapy.
呼吸窘迫综合征期间肌肉注射维生素E对晶状体后纤维增生的影响。
影响因子：
13.7
作者：
Puklin,JE;Simon,RM;Ehrenkranz,RA
通讯作者：
Ehrenkranz,RA